title: New hepatitis C regimen stimulates changes in therapy management.
authors.forename: Thomas
authors.initials: T
authors.lastname: Reinke
mesh_terms: D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy / Q000191:economics; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use; D019468:Disease Management; D004347:Drug Interactions; D006397:Hematinics / Q000191:economics / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011392:Proline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000191:economics / Q000627:therapeutic use; D059039:Standard of Care / Q000191:economics / Q000639:trends*
chemical_list: D000998:Antiviral Agents; D006397:Hematinics; D009842:Oligopeptides; D011480:Protease Inhibitors; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline